Metabolomic Biomarkers of Pulmonary Fibrosis in COVID-19 Patients One Year After Hospital Discharge

Area of Science:

• Pulmonology
• Metabolomics
• Infectious Diseases

Background:

• The COVID-19 pandemic has led to widespread concern regarding long-term health consequences, particularly pulmonary fibrotic sequelae.
• Identifying patients at risk for developing these fibrotic changes post-infection is crucial for timely management.

Purpose of the Study:

• To investigate whether a metabolomic signature in serum samples can predict the development of pulmonary fibrotic sequelae in patients after COVID-19 pneumonia.
• To identify potential biomarkers associated with fibrotic changes one year post-discharge.

Main Methods:

• A prospective, multicenter observational subcohort study (COVID-FIBROTIC) was conducted.
• Serum samples from 109 patients hospitalized with bilateral COVID-19 pneumonia were analyzed using nuclear magnetic resonance (NMR) metabolomics 2 months post-discharge.
• Clinical, functional, and radiological data were collected 1 year after admission to assess for fibrotic sequelae.

Main Results:

• Pulmonary fibrotic sequelae were identified in 33% of patients one year after COVID-19 disease.
• NMR-based metabolomic analysis achieved 80.82% sensitivity and 72.22% specificity (AUC 0.83) in distinguishing patients who would develop radiological signs of pulmonary fibrosis.
• Glucose, valine, and specific fatty acids were identified as potential biomarkers for predicting fibrotic sequelae.

Conclusions:

• A metabolomic signature exists that can predict the development of pulmonary fibrotic sequelae following COVID-19.
• Glucose, valine, and fatty acids show promise as biomarkers for identifying individuals at risk for long-term pulmonary complications after COVID-19.
• These findings support the potential for early, targeted interventions in high-risk patients.